Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI), covering 2026-04-15 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation [Phase 4]